Get the Stockscreener App
29.44
0.57%
-0.17
After Hours:
29.23
-0.21
-0.71%
Overview
News
Price History
Option Chain
Financials
Why TEVA Down?
Discussions
Forecast
Stock Split
Dividend History
Teva Pharmaceutical Industries Ltd Adr stock is traded at $29.44, with a volume of 8.74M.
It is down -0.57% in the last 24 hours and down -14.24% over the past month.
Teva Pharmaceutical, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
See More
Previous Close:
$29.61
Open:
$29.25
24h Volume:
8.74M
Relative Volume:
0.96
Market Cap:
$34.29B
Revenue:
$17.41B
Net Income/Loss:
$1.43B
P/E Ratio:
24.17
EPS:
1.2182
Net Cash Flow:
$1.00B
1W Performance:
+0.48%
1M Performance:
-14.24%
6M Performance:
+60.44%
1Y Performance:
+80.72%
1-Day Range:
$28.89
$29.77
1-Week Range:
$28.38
$30.30
52-Week Range:
$12.46
$37.34
Teva Pharmaceutical Industries Ltd Adr Stock (TEVA) Company Profile
Name
Teva Pharmaceutical Industries Ltd Adr
Sector
Phone
972 (3) 914-8213
Address
TEVA PHARMACEUTICAL INDUSTRIES LIMITED, TEL AVIV
Compare TEVA vs TAK, ZTS, HLN, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.44 | 34.48B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.11 | 56.96B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
115.99 | 49.54B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.23 | 45.90B | 14.54B | 2.22B | 2.58B | 0.4871 |
|
UTHR
United Therapeutics Corp
|
527.00 | 23.24B | 3.18B | 1.33B | 1.04B | 27.90 |
Teva Pharmaceutical Industries Ltd Adr Stock (TEVA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-25 | Initiated | Barclays | Overweight |
| Dec-05-25 | Initiated | Scotiabank | Sector Outperform |
| Jun-06-25 | Initiated | Goldman | Buy |
| May-28-25 | Initiated | Truist | Buy |
| May-12-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-10-24 | Upgrade | Argus | Hold → Buy |
| Mar-08-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Feb-12-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-23-24 | Upgrade | Jefferies | Hold → Buy |
| Jan-03-24 | Upgrade | Piper Sandler | Underweight → Neutral |
| Dec-18-23 | Initiated | HSBC Securities | Buy |
| Nov-27-23 | Upgrade | UBS | Neutral → Buy |
| Jul-06-23 | Upgrade | UBS | Sell → Neutral |
| May-25-23 | Initiated | Morgan Stanley | Equal-Weight |
| May-18-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Jan-19-23 | Downgrade | Jefferies | Buy → Hold |
| Nov-14-22 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-04-22 | Downgrade | UBS | Neutral → Sell |
| Oct-21-22 | Resumed | Jefferies | Buy |
| Aug-05-22 | Upgrade | BofA Securities | Neutral → Buy |
| Jun-14-22 | Resumed | UBS | Neutral |
| May-17-22 | Upgrade | BofA Securities | Underperform → Neutral |
| May-04-22 | Downgrade | Piper Sandler | Neutral → Underweight |
| Apr-05-22 | Upgrade | Barclays | Equal Weight → Overweight |
| Mar-25-22 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Jan-27-22 | Downgrade | Argus | Buy → Hold |
| Oct-28-21 | Downgrade | Raymond James | Outperform → Mkt Perform |
| May-04-21 | Downgrade | UBS | Buy → Neutral |
| Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
| Nov-25-20 | Initiated | Oppenheimer | Perform |
| Aug-06-20 | Upgrade | Barclays | Underweight → Equal Weight |
| Jul-27-20 | Resumed | Goldman | Neutral |
| Jun-01-20 | Upgrade | SunTrust | Hold → Buy |
| Apr-24-20 | Resumed | Citigroup | Neutral |
| Apr-06-20 | Upgrade | UBS | Neutral → Buy |
| Feb-24-20 | Downgrade | Edward Jones | Hold → Sell |
| Nov-12-19 | Upgrade | JP Morgan | Underweight → Neutral |
| Oct-17-19 | Upgrade | Gabelli & Co | Hold → Buy |
| Aug-07-19 | Downgrade | Evercore ISI | Outperform → In-line |
| Jul-19-19 | Initiated | Wolfe Research | Peer Perform |
| Jul-15-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jul-10-19 | Resumed | Credit Suisse | Neutral |
| Jul-05-19 | Upgrade | Argus | Hold → Buy |
| Jun-11-19 | Initiated | Barclays | Underweight |
| Jun-03-19 | Upgrade | Oppenheimer | Perform → Outperform |
| May-30-19 | Downgrade | BofA/Merrill | Buy → Underperform |
| May-28-19 | Downgrade | UBS | Buy → Neutral |
| Mar-20-19 | Initiated | SunTrust | Hold |
| Mar-07-19 | Resumed | UBS | Buy |
View All
Teva Pharmaceutical Industries Ltd Adr Stock (TEVA) Latest News
Teva Pharmaceutical Industries Limited Sponsored ADR Trade Ideas — LS:883035 - TradingView
Tesla Upgraded, Super Micro Computer Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
BIO-Europe Spring® 2026: Partnering Momentum Builds as Global Biopharma Leaders Set Course for Lisbon - GlobeNewswire Inc.
A Look At Teva Pharmaceutical Industries (NYSE:TEVA) Valuation After Branded Drugs Pass $1b Quarterly Revenue - Sahm
How Teva’s Blackstone-Backed ‘Pivot to Growth’ Strategy Could Reshape Teva Pharmaceutical Industries (TEVA) Investors - Sahm
Assessing Teva Pharmaceutical Industries (NYSE:TEVA) Valuation After Pivot To Growth Update At Leerink Conference - Sahm
Teva Blackstone Duvakitug Deal Tests Growth Story And Concentration Risk - Sahm
Teva Drug Updates Support Branded Growth Story And Valuation Upside Potential - Sahm
What's Driving the Market Sentiment Around Teva Pharmaceutical Industries Ltd? - Sahm
Duvakitug IBD Data and TEV-749 Filing Might Change The Case For Investing In Teva (TEVA) - Sahm
Teva to Present at the Upcoming Investor Conferences in March - Sahm
J&J Stock Up 38% in 6 Months: Should You Buy, Sell or Hold? - Finviz
Where is Teva Pharmaceutical Industries Limited (TEVA) Headed? - Finviz
Corcept's Q4 Earnings and Revenues Fall Short of Estimates - Finviz
FDA Accepts Teva's New Long-Acting Schizophrenia Treatment Application - Sahm
Assessing Teva Pharmaceutical Industries (NYSE:TEVA) Valuation After Its Strong Recent Share Price Momentum - Sahm
Truist Boosts Teva (TEVA) Stock Target Amid Pipeline Growth Opportunities - Finviz
Corcept Therapeutics Stock Plunges As Court Clears Teva Generic - Sahm
Goldman Sachs See Teva Pharmaceutical Industries Limited (TEVA) Driving Double-Digit Earnings Growth Through 2026 - Finviz
Teva Pharmaceutical Industries Ltd (TEVA) Stock Price, Trades & News - GuruFocus
Should You Invest in Teva Pharmaceutical (TEVA), Here's What the Street Has to Say - Finviz
Teva (TEVA) Is Down 5.2% After Returning To Profitability On Innovation-Led Revenue Shift – What’s Changed - Sahm
Teva Pharmaceutical Industries (NYSE:TEVA) Valuation In Focus Amid Momentum - Kalkine Media
Here's What Analysts Are Saying About Teva Pharmaceutical (TEVA) Post Earnings - Finviz
Assessing Teva Pharmaceutical Industries (NYSE:TEVA) Valuation After Recent Share Price Momentum And Biosimilar Growth Hopes - Sahm
A Look Into Teva Pharmaceutical Indus Inc's Price Over Earnings - Sahm
Barclays Raises Teva Pharmaceutical (TEVA) PT to $38 Following Strong Q4 Earnings Beat - Finviz
Teva Canada Announces Approval of Expanded Indication of [Pr]AJOVY® (fremanezumab solution for subcutaneous injection), the First Anti-CGRP Preventive Treatment for Pediatric Episodic Migraine - Sahm
Teva Pharmaceutical Industries Limited (TEVA): A Bull Case Theory - Finviz
Teva Canada Mayzent Deal Supports Neuroscience Focus And Valuation Debate - Sahm
FedEx Upgraded, Costco Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Earnings call transcript: Teva Q4 2025 earnings beat expectations, stock rises - Investing.com
Assessing Teva Pharmaceutical Industries’ Valuation After Strong 2025 Earnings And Analyst Upgrades - Sahm
Teva (TEVA) Is Up 7.1% After 2025 Earnings Highlight Branded-Drugs Momentum And Pipeline Progress - Sahm
Analysts See Pipeline Catalysts Driving Teva Pharmaceutical Industries Limited (TEVA)'s 2026 Growth Despite Revenue Headwinds - Finviz
Jim Cramer Highlights Teva Pharmaceutical's Growth Under CEO Richard Francis - Finviz
Is Teva Pharmaceutical Industries (TEVA) Still Attractive After A 92% One-Year Share Price Surge - Sahm
Teva Pharmaceutical Industries (NYSE:TEVA) Reaches New 12-Month High Following Earnings Beat - Defense World
Teva Balances Huntington’s Disease Outreach With Branded Drug Transformation - Sahm
TEVA's Q4 Earnings Beat, Branded Drugs Drive Revenue Growth - Finviz
What Makes Teva Pharmaceuticals (TEVA) a Successful Brand? - Finviz
Teva Pharma stock hits 52-week high at 33.42 USD By Investing.com - Investing.com Nigeria
Teva Pharmaceutical Industries Ltd Adr Stock (TEVA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.63%
2.39%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):